Get the Stockscreener App
781.67
1.41%
10.88
After Hours:
781.67
Regeneron Pharmaceuticals Inc stock is traded at $781.67, with a volume of 726.22K.
It is up +1.41% in the last 24 hours and up +1.35% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$770.79
Open:
$760.91
24h Volume:
726.22K
Relative Volume:
0.84
Market Cap:
$82.64B
Revenue:
$14.34B
Net Income/Loss:
$4.50B
P/E Ratio:
18.81
EPS:
41.5626
Net Cash Flow:
$3.77B
1W Performance:
+0.26%
1M Performance:
+1.35%
6M Performance:
+33.17%
1Y Performance:
+11.23%
1-Day Range:
$760.91
$786.68
1-Week Range:
$753.79
$792.67
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expa - GuruFocus
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline - TradingView
Sarcopenia Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Oncocross, Biophytis, MyMD Pharmaceuticals, Novartis, Regeneron Pharma, Merck - StreetInsider
Why Dupixent Keeps Regeneron A Top Big Pharma Pick - Seeking Alpha
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - The Manila Times
Mitsubishi UFJ Asset Management Co. Ltd. Has $121.55 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Erste Asset Management GmbH Sells 4,661 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Banco Santander S.A. - MarketBeat
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Dupixent’s New FDA Approval For Allergic Fungal Rhinosinusitis - simplywall.st
Regeneron Renews Sponsorship of the Regeneron Science Talent Sear - The National Law Review
K.J. Harrison & Partners Inc Has $2.46 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Dana Investment Advisors Inc. Buys Shares of 5,313 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children - Pharmaceutical Executive
Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036 - GlobeNewswire Inc.
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by TD Asset Management Inc - MarketBeat
FDA approves Dupixent as first treatment for AFRS - The Pharma Letter
Fox Run Management L.L.C. Acquires Shares of 4,413 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years - The Globe and Mail
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Cooling - Yahoo Finance
Should FDA Approval of Dupixent in AFRS Patients Prompt Action From Regeneron Pharmaceuticals (REGN) Investors? - Yahoo Finance
Is Dupixent’s First AFRS Approval Altering The Investment Case For Regeneron Pharmaceuticals (REGN)? - simplywall.st
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis - WebWire
FDA Approves Regeneron's (REGN) Dupixent for Allergic Fungal Rhi - GuruFocus
Regeneron Pharmaceuticals, Sanofi Secure FDA Approval for Dupixent Sinus Treatment - marketscreener.com
Sanofi, Regeneron's Allergic Fungal Rhinosinusitis Treatment Gets US FDA Clearance - marketscreener.com
Sanofi and Regeneron's Dupixent approved in the U.S. for Allergic Fungal Rhinosinusitis - marketscreener.com
Regeneron Pharmaceuticals gains FDA approval for allergy treatment - Traders Union
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis - The Manila Times
Dupixent cuts sinus surgeries, steroids 92% in fungal allergy - Stock Titan
Is Regeneron Pharmaceuticals Inc Gaining or Losing Market Support? - Benzinga
M. Kulyk & Associates LLC Purchases 10,368 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Periodic Fever Market Analysis: Trends, Demand, Size, and Key - openPR.com
FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review - Finviz
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Huda Zoghbi Sells 1,638 Shares - MarketBeat
Is Regeneron (REGN) Still Reasonably Priced After Its Multi Year Share Price Run? - simplywall.st
Regeneron Pharmaceuticals (REGN) Stock Analysis: Navigating Growth with a Promising 11.58% Upside - DirectorsTalk Interviews
Regeneron Pharmaceuticals, Inc. $REGN is Mcdonald Capital Investors Inc. CA's 5th Largest Position - MarketBeat
Lansforsakringar Fondforvaltning AB publ Has $21.55 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Citigroup Inc. Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How (REGN) Movements Inform Risk Allocation Models - Stock Traders Daily
Stevens Capital Management LP Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Ellerson Group Inc. ADV - MarketBeat
Regeneron: A Long-Term Investment in Biotech - Intellectia AI
Regeneron Stock: Here’s Why Four Expected FDA Approvals Could Push its 36% Rally Even Higher - TIKR.com
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850, Maintains Outperform Rating - marketscreener.com
Regeneron Pharmaceuticals, Inc. $REGN is Persistent Asset Partners Ltd's 5th Largest Position - MarketBeat
Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock? - Barchart.com
China Universal Asset Management Co. Ltd. Has $12.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Compass Wealth Management LLC Invests $2.04 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diabetic Macular Edema Market to Reach US$ 7.44 Billion by 2033 - openPR.com
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):